Introduction
Gastric cancer is one of the most common cancers worldwide and the third and fifth leading cause of cancer-related deaths among females and males, respectively. Despite the decrease in incidence and mortality, gastric cancer is still one of the heaviest health burdens worldwide. 1, 2 To date, surgical resection remains the preferred curative method to improve survival of gastric cancer patients. However, for patients who have reached the terminal stage or are not accepted for surgical treatment, chemotherapy is an alternative, but it has some limitations due to its serious side effects. 3 Therefore, it is necessary to elucidate the mechanism underlying gastric cancer development and progression, which will help to develop novel and effective strategies for gastric cancer treatment.
Polo-like kinase 1 (PLK1) is a serine/threonine kinase that participates in the regulation of various processes, including mitosis, cytokinesis, and the DNA damage submit your manuscript | www.dovepress.com
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Xu et al response. 4 A number of studies have shown that PLK1 is highly expressed in multiple digestive tumors, such as esophageal cancer, gastric cancer, colorectal cancer, liver cancer, cholangiocarcinoma, and pancreatic cancer. [5] [6] [7] [8] [9] [10] Additionally, the high expression of PLK1 in gastric cancer is positively related to tumor stage, metastasis, invasion, and poor prognosis. 6, 11, 12 Helicobacter pylori is a common bacterium with a high infection rate, which shows severe pathogenicity. With its unique virulence factors, it can adapt to the highly acidic microenvironment in the stomach cavity, colonize in the host body for a long period of time, and then induce a series of related diseases. Epidemiology confirms that gastritis, peptic ulcer, non-cardia gastric cancer, and low-grade B-cell MALT lymphoma are all associated with H. pylori infection. 13, 14 As early as 1994, the International Agency for Research on Cancer defined H. pylori as a class I carcinogen for gastric cancer, and it may act as a "promoter" to trigger the following cascade lesions: normal gastric mucosa -chronic non-atrophic gastritis -atrophic gastritisintestinal epithelial metaplasia -dysplasia -gastric cancer. 15 According to the data from WHO in 2012, approximately 15.4% of cancers worldwide were attributed to infection. Among these infections, H. pylori infection, which causes gastric cancer, ranks first (35.4%). In China, approximately 24.2% of cancers were attributed to infection, and H. pylori infection-related cancer accounted for 45%. 16 In 2015, the Kyoto global consensus report directly defined H. pylori-positive gastritis as an infectious disease and included it in the "International Classification of Diseases". 17 At the same time, it passed a new consensus that once H. pylori infection is detected, patients need to accept eradication therapy.
H. pylori infection plays a critical role in the process of carcinogenesis through a series of complex regulations. It can promote the proliferation of epithelial cells and directly activate signaling pathways related to early proliferation, leading to increased DNA synthesis and a higher risk of malignant tumors. 18 In our previous study, we found that H. pylori could accelerate PTEN phosphorylation, which activated the PI3K/Akt signaling and promoted cell survival. 19 Furthermore, PLK1 was reported to induce PTEN phosphorylation, activating the PI3K/Akt pathway, which increases tumor susceptibility. 20 Therefore, in this study, we aimed to determine the role of PLK1 in H. pylori infection-induced gastric carcinogenesis. In addition, the effect of H. pylori infection on PLK1/p-PTEN/PI3K/Akt signaling was assessed to identify its underlying mechanisms. Table 1 , and there was no significant difference in the age and gender distribution among these groups. Pathologic diagnosis and classification were carried out as previously described, and all patients were examined for H. pylori infection using Giemsa staining and a rapid urease test. 21 This study was approved by the Medical Research Ethics Committee and the Institutional Review Board of the First Affiliated Hospital of Nanchang University. Written informed consent was obtained from the study subjects.
Materials and methods
Patients and tissue specimens
Mongolian gerbils
Five-to eight-week-old specific-pathogen-free male Mongolian gerbils (30-50 g) were provided by Zhejiang Academy of Medical Sciences (Hangzhou, Zhejiang, China). As previously described, they were maintained in an isolated clean room with a regulated temperature (20°C-22°C), humidity (approximately 55%), and 12/12-h light/dark cycle, with ad libitum rodent diet and water, and then infected with H. pylori after 1 week of observation. 17 Animals were euthanized at 6 months, 12 months, and 18 months post-infection, and linear strips of gastric tissue extending from the squamocolumnar junction through the proximal duodenum were collected. 19 All protocols for animal experiments using gerbils were approved by the ; Abcam) following previously described methods. 21 The negative control sections were incubated with PBS without the primary antibodies. The stained sections were chosen, reviewed, and scored from five randomly selected high-power fields (40× objective lens) by two pathologists blinded to the histopathologic data. Grading discrepancies were re-reviewed and discussed to obtain a final score. Epithelial cells with yellow or brown staining in the nucleus and/or cytoplasm were defined as positive for immunoreactivity. The percentage of immunoreactive cells from 100 cells in each field was averaged from the five fields and scored as follows: 0 5.0% immunoreactive; 1 = 5.1%-25.0%; 2 = 25.1%-50.0%; 3 = 50.1%-75.0%; and 4 75.0%. Moreover, the staining intensity was also semi quantitatively assessed as follows: 0 = no staining; 1 = weak staining; 2 = moderate staining; and 3 = strong staining. The overall protein expression level was then reported as a grade calculated from an integral score of the "area × intensity" as follows: grade 1 = score 0-2 (negative); grade 2 = score 3-5 (weakly positive); grade 3 = score 6-8 (moderately positive); and grade 4 = score 9-12 (strongly positive).
statistical analysis
Data are expressed as a percentage of the control or the mean ± SD. Differences in categorical variables were examined using chi-square tests. Differences in numerical variables, such as patient age, were analyzed using ANOVA among the groups. The differences in numerical variables between differently defined groups were evaluated using Kruskal-Wallis tests or Mann-Whitney tests. p0.05 was considered statistically significant.
Results
PlK1 is upregulated in gastric cancer tissues
Western blot was performed to assess PLK1 expression in protein samples from gastric cancer tissues and the paired adjacent mucosa of patients. An increase in PLK1 expression was detected in gastric cancer tissues compared to the paired adjacent mucosa (23/26, 88.46%) (Figure 1 (Figure 2A and C) . These data suggest that PLK1 may contribute to gastric carcinogenesis at the early stage.
As it has been postulated that H. pylori infection may trigger gastric carcinogenesis, the same cohort of patients were divided into H. pylori-positive and -negative groups, and the expression of PLK1 was compared between these two groups. Immunohistochemical analysis revealed that there was a significant difference among these four groups in H. pylori-positive patients. PLK1 expression was decreased 
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PlK1 is involved in H. pylori-mediated gastric carcinogenesis in chronic non-atrophic gastritis compared to intestinal metaplasia, dysplasia, and gastric cancer tissues from H. pylori-positive tissues (p0.05) ( Figure 2D ). Furthermore, in intestinal metaplasia tissues, PLK1 was much higher in H. pylori-positive patients than in H. pylori-negative patients (p0.001) (Figure 2B and D) . These results suggest that PLK1 is related to H. pylori infection in the process of gastric carcinogenesis.
H. pylori infection induces high expression of PlK1 in gastric tissue from Mongolian gerbils
To confirm that PLK1 is related to H. pylori infection in the process of gastric carcinogenesis in vivo, we performed immunohistochemical analysis of PLK1 in gastric tissue samples of Mongolian gerbils with or without H. pylori infection. Our results showed that expression of PLK1 was greatly enhanced in the H. pylori-positive group compared to the H. pylori-negative group at all time points, such as at the 6th month, the 12th month, and the 18th month postbacterial inoculation (p0.05, p0. 01, p0.001). In addition, the significance was more obvious with longer H. pylori infection (Figure 3 ).
PlK1 is involved in H. pylori-promoted cancer cell proliferation
Cell proliferation assessment using a CCK8 assay showed that H. pylori could increase MKN-28 cell viability in both dose-and time-dependent manner (p0.05) ( Figure 4A ). To determine the role of PLK1 in H. pylori-promoted cancer To further confirm the effect of H. pylori infection on activation of the PLK1 and Akt pathway, we incubated MKN-2 8 cells with H. pylori (MOI = 200) at different time points. We found that the expression levels of PLK1 and cyclin D1 and the ratios of p-PTEN/PTEN, p-Akt/Akt, and p-Bad/Bad were increased in a time-dependent manner (p0.05); however, there were no significant differences in the control (Figure 6A and B) .
To certify whether H. pylori-induced activation of Akt pathway is dependent on PLK1, we used the PLK1 inhibitor BI 2536 to pretreat MKN-28 cells prior to H. pylori infection. We found that after H. pylori infection, expression levels of PLK1, p-PTEN, p-Akt, cyclin D1, and p-Bad were significantly decreased in the BI-2536-treated group compared to the DMSO and the untreated group (p0.05) (Figure 7) , suggesting that PLK1 is involved in H. pylori infection-induced activation of the Akt pathway.
Discussion
Development of gastric cancer is a multistaged and orderly process, which proceeds from normal mucosa to chronic non-atrophic gastritis, intestinal metaplasia, dysplasia, and finally gastric cancer. H. pylori infection often plays the initial and leading role in this process. We previously reported that increased PTEN phosphorylation at residues Ser380/ Thr382/383 contributed to H. pylori infection-induced gastric carcinogenesis.
19 PLK1 could promote PTEN phosphorylation at these residues. 22 Therefore, the present study focused on the unknown role of PLK1 in H. pylori-regulated cancer occurrence and development.
Normally, PLK1 is expressed highly in tissues with an actively proliferating cell population, and PLK1 is expressed poorly in gastric tissues. Jang et al 23 detected the expression of PLK1 in 280 patients with gastric cancer and found that 95% of cancer patients had high expression of PLK1, while there was almost no expression of PLK1 in its paired adjacent mucosa, which is consistent with our findings. A sustained increase of PLK1 in intestinal metaplasia, dysplasia, and gastric cancer tissues could be detected in our study. Additionally, the data showed that PLK1 was significantly lower in patients with chronic non-atrophic gastritis who were infected with H. pylori, but there was no significant difference among patients at later stages, suggesting that PLK1 related to H. pylori may contribute to gastric carcinogenesis at the early stage. To confirm the human sample results, we established H. pylori-infected Mongolian gerbil models to further demonstrate the role of PLK1 in H. pylori-induced 
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PlK1 is involved in H. pylori-mediated gastric carcinogenesis cancer occurrence. We found that PLK1 expression was positively related with the duration of H. pylori infection, which supported our human sample results.
According to numerous studies and our preliminary experiments, PTEN can negatively regulate the PI3K/Akt pathway, and the latter is important in promoting proliferation, controlling cell survival, and inhibiting apoptosis.
24-27 Our present study revealed that H. pylori infection could increase expression of PLK1, thus inducing PTEN phosphorylation and then the activation of the PI3K/Akt pathway. Meanwhile, 
5710
expression of p-PTEN, p-Akt, cyclin D1, and p-Bad began to increase 30 min after H. pylori infection and continued throughout the duration of the infection. The control group, which was not exposed to infection, exhibited no significant changes in the expression of p-PTEN, p-Akt, cyclin D1, and p-Bad. This suggests that H. pylori may activate the PTEN/ Akt signaling pathway at the early stage of infection in vitro. Furthermore, a broad range of studies confirmed that H. pylori infection could activate the Akt signaling pathway at the early stage. 19, 28, 29 We, therefore, hypothesized that at the early stage , H. pylori also secretes many other virulence factors, including iceA, oipA, urease, babA2, Lewis b, hrgA, dupA, picA, picB, and so on. These virulence factors encode genetic polymorphism of their proteins which can cause different pathogenicity of H. pylori and then determine the clinical outcome of H. pylori infection-related diseases. However, the virulence factors responsible for PLK1/Akt interactions and related cancer prognosis are still not clear.
Conclusion
We confirmed the role of PLK1/p-PTEN/PI3K/Akt in H. pylori-induced carcinogenesis (detail in Figure 8 ). The elucidation of this mechanism may aid the development of new control strategies for H. pylori infection-related disease.
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